European Archives - Page 542 of 1425 - European Medical Journal

Better Outcomes in Myocarditis After COVID-19 Vaccination

Myocarditis following a COVID-19 mRNA vaccine is associated with less severe cardiovascular events compared to myocarditis from other causes.

Researchers Identify Optimal Mammography Frequency for Improved Outcomes

Research shows annual mammograms lower late-stage breast cancer risk and improve survival compared to less frequent screening

NICE endorses Novartis’ take home drug for rare blood disorder

NICE recommends an oral therapy for adults with PNH, marking the 1000th medicine evaluated since its inception in 1999.

From data to decision-making: How AI will transform medical affairs

AI is becoming less of a buzzword for those in the pharma industry. For medical affairs teams, how will it transform the function’s future?

Dengue Versus COVID-19: Long-Term Health Risks

Study shows that survivors of dengue face significantly higher risks of long-term cardiovascular and neuropsychiatric complications compared to those who recovered from COVID-19.

Majority of Iron Deficiency Cases Remain Unresolved After 3 Years

A recent study from a Minnesota statewide health system has revealed concerning data about the persistence of iron deficiency among patients.

Optimising Methotrexate – How to Achieve Maximum Results with the Anchor Drug of Rheumatoid Arthritis Therapy

Learn more about the management of patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and psoriatic arthritis…

Which MRI Features Predict Recurrence of Brain Metastases?

Research has identified specific imaging biomarkers that can help predict the risk of recurrence in patients with brain metastases treated with stereotactic radiotherapy.

MRI-Based System Improves Diagnosis of Extremity Infections

A study showed a new MRI-based Musculoskeletal Infection Reporting and Data System, designed to enhance diagnostic accuracy for peripheral extremity infections.

Sanofi's MS drug delivers surprising Phase III results

It’s been both a good and bad week for French pharmaceutical company Sanofi, as their MS drug candidate, received mixed trial results.